What is analytical method validation under ICH Q2(R2) and Q14?

Analytical method validation ensures reliable and compliant data throughout drug development. With the introduction of ICH Q2(R2) and Q14, expectations around method development, validation and lifecycle management have significantly evolved.

Analytical method validation is a critical and a widely studied process in industries such as pharmaceuticals, food safety, biotechnology, and environmental monitoring, particularly within the Chemistry, Manufacturing, and Controls (CMC) framework in drug development. The objective of validating an analytical procedure is to demonstrate that the process is fit for the intended purpose, ensuring sufficient accuracy, precision, specificity, and consistency to support regulatory decision-making. Without validated analytical procedures, a regulatory submission cannot credibly demonstrate product quality, safety, or efficacy. For over two decades, the global standard governing this process was ICH Q2(R1), a guideline that dated to the mid-1990s.

In November 2023, the International Council for Harmonization (ICH) adopted two landmark documents that modernized the entire field: ICH Q2(R2), a comprehensive revision of the validation guideline, and ICH Q14, an entirely new guideline on analytical procedure development. Both became legally effective on 14 June 2024 in the EU and were published by the FDA in March 2024. Together, Q2(R2) and Q14 outline the modern regulatory expectations for analytical method development, validation, and submission strategy across both EMA and FDA. The two guidelines are fundamental to the CMC regulatory framework, and their outputs, validation protocols, development data, and performance evidence constitute a vital component of Module 3 of the Common Technical Document (CTD), which regulators scrutinize most rigorously during the evaluation of a marketing authorization application. ^1-5

Scope of ICH Q2R2 and applicability

The guideline for the validation of analytical procedures, as stipulated in the International Council for Harmonization, ICH Q2(R2): Validation of Analytical Procedures, is a guideline that provides regulatory guidance on the validation of analytical procedures in ensuring the quality of pharmaceuticals. This guideline is relevant in ensuring the quality of analytical procedures in the release and stability tests of commercial drug substances and drug products, such as chemical, biological, and biotechnological substances/products. It could also be relevant in ensuring the quality of other analytical procedures in the control strategy, following a risk-based approach as per the pharmaceutical quality system and ICH Q10 guidelines.

The scope of the ICH Q2(R2) guideline is essentially the same as the scope of the ICH Q2(R1) Validation of Analytical Procedures guideline. These include the analytical procedures for the assay or potency of the drug substance or product, purity tests, impurities by quantitative or limit tests, identity tests, etc. Nevertheless, Q2(R2) also includes increased flexibility and technology coverage, driven by e.g. new biological and cell-based drug modalities, reflecting advances in analytical science and its integration into lifecycle approach-based method development tools as described in ICH Q14 Analytical Procedure Development. Compared to Q2(R1), this updated guideline enhances the level of guidance and promotes a science- and risk-based approach to validation, while maintaining the original breadth of categories in the analytical process (ICH, 2023).^4,6-9

Alignment with EMA and FDA expectations

The European Medicines Agency (EMA) and the United States' Food and Drug Administration (FDA) have already adopted the new version of the guidelines ICH Q2(R2) Validation of Analytical Procedures and ICH Q14 Analytical Procedure Development into the regulatory process. In the United States, the availability of the final version of the guidelines has been announced by the Food and Drug Administration in the Federal Register on the 7th of March 2024, which confirms the adoption of the new version into the regulatory process. It has been mentioned in the announcement that the new version of the guidelines provides harmonized principles to be followed in the validation and development of analytical procedures and are expected to assist regulatory evaluation and provide flexibility in managing post-approval changes with appropriate scientific justification.

Likewise, the European Medicines Agency has also implemented the ICH Q2(R2) and Q14 guidelines as part of the European regulatory process, with both guidelines being legally effective as of 14 June 2024. Even though both agencies follow the identical ICH guidelines, there may be some differences in terms of regulatory expectations during the scientific evaluation process. For example, regulatory authorities may require different information with respect to robustness study information, lifecycle documentation, or historical knowledge with respect to the development of analytical methods. It is important that companies look at developing strategies that meet the expectations of both regulatory authorities at the outset.^4,5,10,11

The relationship between ICH Q2R2 and ICH Q14: Analytical method lifecycle

In the current pharmaceutical quality system, the lifecycle of the analytical procedure has been defined in the ICH Q2(R2) and the ICH Q14. While the ICH Q14 specifically deals with the science of the analytical method development/lifecycle management, including the approach to the risk management and post-approval change management strategies, the ICH Q2(R2) provides the guideline for demonstrating that the analytical procedure that has been developed is validated and appropriate for its intended purpose.^2,12

ICH Q2(R2) and Q14 are interdependent guidelines, and a full understanding of analytical procedure validation requires considering them in conjunction. They are incorporated into the wider ICH quality framework, specifically, the interrelated standards ICH Q8(R2) (Pharmaceutical Development), Q9(R1) (Quality Risk Management), Q10 (Pharmaceutical Quality System), Q11 (Drug Substance Development) and Q12 (Lifecycle Management). Collectively, these guidelines characterize a risk- and science-based policy in addressing product and process quality across the development and commercial lifecycle. ICH Q14 explicitly applies the lifecycle approach to analysis processes, making validation not a single event but a permanent process of dedication to the performance of methods.

The updated guideline acknowledges the possibility of calibration algorithms being both linear and non-linear and suggests that the model performance should be evaluated throughout the calibration range. This shift is attributable to the increasing application of enhanced analytical methods like near-infrared (NIR) spectroscopy, Raman spectroscopy and process analytical technology (PAT) in the analysis of pharmaceuticals. Techniques such as PCR, cell-based assays, and binding assays, are now explicitly incorporated within the expanded scope of Q2(R2), reflecting the significant growth in biotherapeutics since the original guideline was written. Finally, the new guideline formally introduces the concept of validation during the lifecycle, addressing partial or full revalidation when changes occur, and co-validation for multi-site scenarios, concepts that were absent from R1.^13,14

The strategic impact of ICH Q14 on validation design

ICH Q14 formally acknowledges two types of analytical procedure development: the minimal (standard) approach and the enhanced, Quality by Design (QbD-)based approach. The minimal approach is based on the conventional method development practice, while the enhanced approach employs the systematic approach that involves the use of prior knowledge, risk assessment, design of experiments (DoE), and a structured control strategy. One of the central ideas presented by Q14 is the Analytical Target Profile (ATP), a prospectively established set of performance standards that the method needs to reach to fulfill its intended goal.

The ATP is the cornerstone of all further development and serves as the foundation on which one may be validated under Q2(R2). In case of an incorrect definition of the ATP, a method can be out of purpose, even after it has been validated technically. The improved analytical  method development strategy also facilitates the establishment of a Method Operable Design Region (MODR), a multidimensional space within which the method is likely to be reliable. Furthermore, Proven Acceptable Ranges (PARs) can be established for specific method parameters using univariate testing to ensure consistent method performance within defined limits. MODR reflects the combined effects of multiple parameters usually established through Design of Experiments (DoE), whereas PARs describe acceptable ranges for single parameters. Techniques designed in an MODR or using PARs could receive a more lenient regulatory route to post-approval amendments through ICH Q12, potentially alleviating the regulatory burden of future lifecycle modifications.¹⁵

Key analytical requirements and documentation

The core validation parameters remain consistent with those established in Q2(R1), but Q2(R2) brings considerably more precision to their definition, measurement, and documentation.

Accuracy, precision and specificity/selectivity

Accuracy is the closeness of agreement between measured values and a reference (true) value. Under Q2(R2), accuracy may be established using spiked samples, comparison with a reference method, or, for biotherapeutics, through alternative approaches that account for the inherent heterogeneity of biological matrices. Q2(R2) further emphasizes the use of confidence intervals for measuring analytical performance characteristics such as accuracy and precision. Additionally, the guidelines now explicitly allow the use of a combined approach to demonstrate both accuracy and precision simultaneously, a statistically more robust method than separate point estimates. A recent survey of over 100 industry stakeholders found that 76% of respondents had concerns about the new confidence interval requirement for accuracy and precision, with 40% worried about needing more replicates and 21% noting they lacked sufficient data to set acceptance criteria. This underscores the need for early statistical planning in validation study design.¹⁶

Specificity, the ability to properly assess an analyte in the presence of others, is critical. Although in practice most analytical methods are considered selective rather than truly specific. In chromatographic techniques, selectivity testing is accomplished by evaluation of resolution of key peak pairs. In biological assays, the problem is more complex as selectivity must be validated against a broader spectrum of endogenous interferents, and similar species.

Linearity, range, LOD and LOQ

As mentioned earlier, Q2(R2) substitutes the concept of linearity with working range, which reflects the fact that many contemporary analytical processes, especially ones that involve multivariate or biological calibration models, are not linear over their operating range. Moreover, the desired range of the analytical method considers the reporting limits such as the LOQ and the assay’s intended purpose. The working range is specified in relation to the reportable range for clarity: the working range is the range of sample concentrations or activities within which the procedure will be employed, while the reporting range establishes the interval across which results can be reliably reported.

The Detection Limit (LOD) and the Quantitation Limit (LOQ) requirements are maintained but are more contextualized in the framework of the lifecycle. LOD and LOQ should be addressed in the context of the assay specification limit, ensuring that limits are appropriate to the assay’s intended purpose and reporting. Additionally, in techniques that are operated close to their quantification limit, such as impurity assays or trace-level degradation studies, Q2(R2) gives a bit more detail on how to establish and report these limits, including signal-to-noise methods, calibration curve-based methods, and visual inspection. It is still recommended to have at least five concentrations to establish the calibration range.

Robustness and system and sample suitability

Robustness, the ability of a procedure to be unresponsive to minor yet intentional changes in method parameters, is one of the predictors of the long-term behavior of standard GMP laboratories. In the context of Q2(R2), robustness is more closely related to the development of the method: the data obtained in the context of method development of  the Critical Method Parameters (CMPs) can be utilized to support the validation inferences, and one may not need to conduct additional post-development robustness studies if the method has been developed using a systematic, QbD-based approach that evaluates CMPs and method performance.  

In practice, one of the most commonly mentioned weaknesses in both FDA warning letters and EMA inspection results is poor robustness documentation. Among the most important updates to ICH Q2(R2) is the addition of guidance about increased robustness investigation required in complex analytical methods such as those applied to biotherapeutics. Suitable robustness testing results in a meaningful set of system and sample suitability criteria, designed to confirm the method’s ability to meet the intended purpose within each analytical run.

System suitability testing (SST) and sample suitability criteria are an inseparable part of approved procedures. SST parameters and predefined criteria for sample suitability should be set and recorded in the validation protocol and method documentation.¹⁷

Documentation in Module 3 of the CTD

The information on the validation and development of analytical methods is recorded in Module 3 (Quality) of CTD. This part of the dossier presents regulating bodies with arguments that release and stability testing undertaking is scientifically based, properly validated and fit to undertake routine quality control in. Validation reports often contain a sufficiently detailed description of the actual analytical procedure, the validation protocols, the acceptance criteria, the results, and the raw data or summaries that indicate the adherence to the mentioned requirements in the validation process.

The introduction of ICH Q14 Analytical Procedure Development expands what companies may include in regulatory submissions regarding analytical method development. In previous practices, dossiers typically included the main emphasis on final validation results, with little details on the development of the method. Q14 enables applicants implementing the enhanced development approach to provide selected data on analytical procedure development, and validation data. Such supplementary information can assist regulators in gaining a better insight into method robustness, performance limits, and the scientific basis of critical method parameters.

The provision of development knowledge can also serve more formal lifecycle management approaches. When the development of analytical procedures includes the clearly defined performance criteria like an Analytical Target Profile (ATP) and follows other principles of the enhanced approach, such as establishing a Method Operable Design Region (MODR), the information may be used to support future post-approval change management. This can in certain instances facilitate implementation of regulatory measures like the post-approval change management guidelines outlined in the ICH Q12 Technical and Regulatory Considerations of Pharmaceutical Product Lifecycle Management, which could allow some changes in methods to be executed with less regulatory reporting when the changes do not alter the established control strategy.^4,10,18,19

Continued performance verification

After a method is approved and in routine GMP use, it must continue to perform within its validated parameters. Continued performance verification involves ongoing monitoring of system suitability data, trending of key performance indicators, and periodic review of out-of-specification (OOS) events to identify potential method drift. Under a Q14 enhanced approach, this monitoring can be formalized as part of the method's control strategy, enabling proactive identification of issues before they affect product release decisions.

Change management and revalidation triggers

As explicitly stated in ICH Q2(R2), changes during the lifecycle of a validated procedure may require partial or full revalidation. Science- and risk-based principles should be used to determine which performance characteristics are impacted by a given change and what level of revalidation is therefore necessary. Methods developed under the Q14 enhanced approach, with a well-characterized Proven Acceptable Ranges (PARs) for single parameter range and a Method Operable Design Region (MODR) for multidimensional parameter combined effects, can accommodate a wider range of changes without triggering regulatory submissions, because the boundaries of acceptable variation have been prospectively defined and agreed with regulators. This represents a meaningful reduction in compliance burden for companies with a strong analytical development strategy.¹

The guideline specifies that when transferring to a different laboratory, either a partial or full revalidation of relevant performance characteristics should be conducted, or a comparative analysis of representative samples (co-validation) should be performed. If necessary, the reason for not performing additional transfer tests should also be recorded.

Comparative testing during transfer

Effective transfer of methods needs a pre-designed transfer protocol, which outlines the performance parameters to be measured, acceptance criteria, the number of replicates and the statistical method to be used in comparing results between source and receiving sites. Historical inter-laboratory variability data during the development phase can be used to establish equivalence criteria when complex analytical techniques are used, especially biological assays, which are expected to have more substantial variability. The use of reference standards and qualified reference materials should be well documented as bridging strategies. Any variation in results between sending and receiving site that exceeds acceptance thresholds that are not stipulated in advance must be traced and fixed prior to the transfer being considered complete.

Data integrity and inspection expectations

Non-negotiable requirements in transferring methods and in the routine GMP utilization include data integrity, completeness, consistency, and accuracy of analytical data during its lifecycle. Indeed, to ensure compliance these requirements must be met by adhering to ALCOA+ principles, guaranteeing that data is attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring and available. In GMP inspections both EMA and FDA inspectors examine audit trails, instrument qualification records and laboratory information management system (LIMS) data. Poor documentation of validation and weak data traceability continue to be recurrent themes in FDA warning letters, such as warning letters regarding analysis methodology and system suitability.

Validation strategies for synthetic molecules vs biotherapeutics

While Q2(R2) applies to both synthetic molecules and biotherapeutics, the validation challenges differ substantially between these two molecule classes, and the expanded scope of the revised guideline is designed to address this more explicitly.

Analytical challenges with biotherapeutics

Biotherapeutics, including but not limited to monoclonal antibodies, biosimilars, and advanced therapy medicinal products (ATMPs), present unique validation challenges due to their structural complexity, heterogeneity, and susceptibility to process-related variation. In the context of biosimilar analytical similarity assessments, for instance, the use of orthogonal analytical tools is often used, as methods that use different physicochemical or biological principles to assess the same attribute provide independent, complementary evidence of quality.

Potency assays for biotherapeutics, cell-based assays, receptor-binding assays, and enzyme activity assays, are inherently more variable than synthetic molecule assays. ICH Q2(R2) acknowledges this by providing expanded guidance on calibration models for assays with S-shaped responses (e.g., four-parameter logistic models), and by allowing alternative approaches to accuracy and precision that are appropriate for biological matrices. ICH Q14 case studies include examples specifically developed for monoclonal antibodies and chiral impurity analysis, illustrating how the enhanced approach concepts can be applied to complex biological and stereochemical analytical challenges.²⁰

Incomplete robustness studies

Robustness studies are commonly either overlooked or performed in a very limited fashion, only a few of the relevant method parameters are tested. Under Q2(R2) a risk-based approach should be used to determine which parameters affect method performance. In enhanced approaches to method development, DoE allows multiple parameters to be evaluated simultaneously, eliminating the need to test each parameter individually. Additionally, PARs and MODRs as determined during the enhanced approach provide flexibility to work consistently within a range around set points. If this is not the case, strict adherence to the validated method’s established set points is required. One of the most prevalent reasons behind regulatory queries in Module 3 reviews is incomplete robustness data.

Weak documentation and traceability

Q2(R2) specifies that every validation data, such as raw data, calculations, and methodology should be traceable in full, in line with ALCOA+ principles, and provided in Module 3. The findings of the inspection regularly employ the absence of raw data or the ambiguity of connections among versions of methods and verification studies. Since validation conclusions can now be supported by development data, the trail of documentation between ATP and development experiments through formal validation has to be sensible and traceable.

Insufficient method transfer data

Method transfer is a well-recognized risk point in pharmaceutical quality systems. Insufficient transfer data, particularly for complex biological assays, can leave a company unable to demonstrate equivalence between originating and receiving laboratories at the time of regulatory inspection or during batch release. Pre-defined acceptance criteria, backed by inter-laboratory variability data from development, are essential components of a defensible transfer protocol.

Strategic considerations for biotech companies

Analytical method validation should be treated as a strategic CMC decision, not a regulatory checkbox to be completed at the end of development. The choices made during analytical development, including whether to pursue a minimal or enhanced approach under Q14, have long-term consequences for regulatory flexibility, lifecycle management costs, and the speed of post-approval changes.

Early analytical planning

The most effective validation strategies are those that are planned from the beginning of analytical development, not retrospectively constructed from available data at the point of submission. Developing ATP at an early stage, specifying the parameters of critical methods using risk analysis and DoE, and creating a recorded history of development since the Phase I submission package forms the basis of a strong and defensible Q2(R2)/Q14 submission package. Early analytical planning also allows resource allocation to be more effectively achieved: development information gathered within a specific Q14 framework can immediately be used to shorten the steps that must be formally validated, and the risks of poor robustness can be found out early enough to prevent late-stage surprises that delay submissions.

Outsourcing vs in-house validation

A significant proportion of biotech firms, especially those lacking their own dedicated laboratories, collaborate with CROs or contract testing organizations for analytical development and validation. CROs use specialized expertise, advance analytical infrastructure and experience in a wide range of therapeutic modalities, allowing for faster method development and robust validation. Using this expertise enables businesses to maintain high quality data, extensive documentation, and solid procedure knowledge while taking advantage of external resources.

Firms undertaking analytical validation under Q2(R2)/Q14 must be careful to include in the contractual agreements the specifications of data format and transfer requirements, align the CRO SOPs with the quality management system of the company, and ensure that external development data is recorded in a format that is compatible to be incorporated as part of regulatory filings without generating traceability differences.^1,2,21-24

Frequently asked questions on ICH Q2R2 and Q14 validation

Why is analytical method validation important?

Analytical method validation under ICH Q2(R2) makes sure that tests used for quality control and drug development are accurate, reliable and can be repeated. Poorly validated methods can lead to regulatory problems, delays in approval, and problems with EMA and FDA submissions.

What are the advantages of working with an expert CRO for analytical method validation and development?

Working with an expert CRO provides biotech and pharmaceutical companies with advanced analytical expertise, cutting-edge instrumentation and proven regulatory experience in method development and validation for small molecules, biotherapeutics. Expert CRO accelerate method development, ensure regulatory-compliant validation under ICH Q2(R2) and Q14, reduce FDA and EMA risks, and produce reproducible results, allowing businesses to streamline product development while maintaining high quality standards.

Is the enhanced Q14 approach mandatory?

No. The traditional (minimal) approach stands. Nonetheless, firms investing in the improved methodology including ATPs, MODRs, PARs and extensive history of development do receive a wider range of post-approval regulatory flexibility as ICH Q12 permits. This can provide a big benefit and cost-effectiveness in the long-term, especially in the case of products whose analytical processes are a complex or developing process.

Can development data from before June 2024 be used in Q14-aligned submissions?

Yes. ICH Q2(R2)/Q14 also enable the development data of the past to be employed to assist the validation but must meet the specified quality and relevance standards. While the data was not prospectively described as being Q14-compliant, documentation and traceability are the most important requirements.

What is the difference between the Analytical Target Profile (ATP) and a method specification?

An analytical methodology ATP outlines the performance standards that the analytical process should achieve its intended use - it is a development tool and regulatory communication document. By comparison, a method specification identifies how the product attribute under measurement should be accepted. The ATP guides the design of the method; the specification identifies the passing of a batch or the failure of a batch.

How does Q2(R2) handle validation for biological assays with high variability?

Q2(R2) explicitly acknowledges that biological assays, including cell-based assays and immunoassays, may have non-linear response curves and inherently higher variability than chemical assays. The guideline allows alternative calibration models (e.g., four-parameter logistic), replication strategies, confidence interval-based approaches to accuracy and precision, and flexibility in acceptance criteria, provided these are scientifically justified and agreed with regulators.

References

1. ICH (2023a). ICH Q2(R2): Validation of Analytical Procedures. Final Version, November 2023. Assessed from https://database.ich.org/sites/default/files/ICHQ2(R2)Guideline20231130.pdf.
2. ICH (2023b). ICH Q14: Analytical Procedure Development. Final Version, November 2023. Assessed from https://database.ich.org/sites/default/files/ICH_Q14_Guideline_2023_1116_1.pdf
3. ICH (2005). ICH Q2(R1): Validation of Analytical Procedures: Text and Methodology. Assessed from https://database.ich.org/sites/default/files/Q2(R1)%20Guideline.pdf.
4. EMA (2024a). ICH Q2(R2) Validation of Analytical Procedures – Scientific Guideline. Legal effective date: 14/06/2024. Assessed from https://www.ema.europa.eu/en/ich-q2r2-validation-analytical-procedures-scientific-guideline
5. Q2(R2) Validation of Analytical Procedures and Q14 Analytical Procedure Development; International Council for Harmonisation; Guidances for Industry; Availability. Assessed from https://www.federalregister.gov/documents/2024/03/07/2024-04834/q2r2-validation-of-analytical-procedures-and-q14-analytical-procedure-development-international
6. INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE PHARMACEUTICAL QUALITY SYSTEM Q10. Assessed from https://database.ich.org/sites/default/files/Q10%20Guideline.pdf.
7. Q2(R2) Validation of Analytical Procedures Guidance for Industry. Assessed from https://www.fda.gov/media/161201/download.
8. INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE VALIDATION OF ANALYTICAL PROCEDURES Q2(R2). Assessed from https://database.ich.org/sites/default/files/ICH_Q2-R2_Document_Step2_Guideline_2022_0324.pdf.
9. New ICH Q2 (R2) and ICH Q14: a Step Forward Towards the Validation of Analytical Methods. Assessed from https://blog.pqegroup.com/ra-phv/new-ich-q2-r2-and-ich-q14?
10. Q2(R2) Validation of Analytical Procedures. 2024. Assessed form https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q2r2-validation-analytical-procedures?
11. ICH Q14 Analytical procedure development - Scientific guideline. Asdessed from https://www.ema.europa.eu/en/ich-q14-analytical-procedure-development-scientific-guideline?
12. Q14 Analytical Procedure Development. Assessed from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q14-analytical-procedure-development?
13. INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1). Assessed from https://database.ich.org/sites/default/files/Q2_R1__Guideline.pdf.
14. Cassidy, B., Bloomingdale, T., & Carmody, J. (2025). Navigating ICH Q2 (R2) compliance in analytical method validation: A gap analysis toolkit to streamline risk assessment and change management. Journal of Pharmaceutical Sciences, 114(6), 103749.
15. Applying ICH Q14 in Pharmaceuticals Part 1: The Application of Analytical Target Profile in Analytical Method Development. Assessed from https://premier-research.com/perspectives/applying-ich-q14-in-pharmaceuticals-part-1-the-application-of-analytical-target-profile-in-analytical-method-development/.
16. Streamlining Analytical Procedure Development, Validation, and Change Management: ICH Introduces Q2(R2) and Q14 Guidelines. Assessed from https://ispe.org/pharmaceutical-engineering/ispeak/streamlining-analytical-procedure-development-validation-and.
17. A look at how robustness studies might be conducted in light of recent ICH guideline updates. Assessed from https://biopharmaspec.com/blog/updates-on-robustness-studies/
18. ICH Q12 Technical and regulatory considerations for pharmaceutical product lifecycle management - Scientific guideline. Assessed from https://www.ema.europa.eu/en/ich-q12-technical-regulatory-considerations-pharmaceutical-product-lifecycle-management-scientific-guideline?.
19. ICH Q12: A Transformational Product Life-Cycle Management Guideline. Assessed from https://ispe.org/pharmaceutical-engineering/may-june-2020/ich-q12-transformational-product-life-cycle-management?
20. Nupur, N., Joshi, S., Gulliarme, D., & Rathore, A. S. (2022). Analytical similarity assessment of biosimilars: global regulatory landscape, recent studies and major advancements in orthogonal platforms. Frontiers in bioengineering and biotechnology, 10, 832059.
21. CMC and Analytical Gaps in CRLs: Why They Persist Despite FDA Guidance and How You Can Position Yourself for Success. Assessed from https://www.pharmtech.com/view/cmc-and-analytical-gaps-in-crls-why-they-persist-despite-fda-guidance-and-how-you-can-position-yourself-for-success.
22. Understanding the Lifecycle Approach for Analytical Procedures. Assessed from https://www.chromatographyonline.com/view/understanding-lifecycle-approach-analytical-procedures.
23. Charoo, N. A., Khan, M. A., & Rahman, Z. (2023). Data integrity issues in pharmaceutical industry: Common observations, challenges and mitigations strategies. International journal of pharmaceutics, 631, 122503.
24. Eberle, M., Wasylenko, J. T., Kostelac, D., Kiehna, S., Schellinger, A., Zhang, Z., & Ehrick, J. D. (2024). A modern framework for analytical procedure development and lifecycle management based on ICH Q14 principles. Analytical Chemistry, 97(1), 12-21.